[Treatment guidelines for venous leg ulcers: causal therapy initiation and local wound treatment].
Treatment of leg ulcers should consider two aspects, i.e. the exact underlying condition (main cause and contributing factors) and local conditions. Compression therapy remains the corner-stone of the therapeutic concept. A compression of 35 mmHg at the distal calf improves insufficient venous function. A systolic ankle pressure of < or = 80% of blood pressure (ankle-arm-index < or = 0.8) requires reduction of compression therapy. At an ankle pressure below 80 mmHg compression should not be used. If superficial reflux is the major cause of chronic venous insufficiency, vein stripping should be considered. Contributing diseases like heart insufficiency, anemia or diabetes may require general medical care. Local contributing factors like reduced mobility of the ankle joint and lymphostasis may require physical therapy, and calcification of the wound bed should be excised. Local treatment considers ulcer bed and border. The ulcer bed needs debridement and moist wound care. Infection is treated with systemic antibiotics, according to the antibiogram. Tetanus immunization is required for all leg ulcer patients. Some centers report good results with endoscopic subfascial decision of perforator veins, paratibial fasciotomy and excision of fibrous tissue. Local application of recombined growth factors is currently under clinical evaluation. Adjuvant pharmacotherapy plays a minor role in the treatment of venous leg ulcers. An efficient treatment of the underlying cause combined with optimal wound care are the key to therapeutic success.
Hafner
J
J
Dermatologische Klinik und Poliklinik, Universitätsspital Zürich.
Brunner
U
U
Burg
G
G
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001458:Bandages; D003646:Debridement; D006801:Humans; D007871:Leg Ulcer / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D010982:Platelet-Derived Growth Factor / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011312:Pressure; D013745:Tetanus Toxoid / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000627:therapeutic use; D014689:Venous Insufficiency / Q000150:complications; D014946:Wound Infection / Q000517:prevention & control
D000900:Anti-Bacterial Agents; D010982:Platelet-Derived Growth Factor; D013745:Tetanus Toxoid; D016212:Transforming Growth Factor beta
Behandlungs-Richtlinien für venöse Beinulzera: Kausaler Therapieansatz und lokale Wundbehandlung.